AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat ...

Earnings Call Insights: Daiichi Sankyo (OTCPK:DSKYF) Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% ...

Daiichi Sankyo now expects Enhertu could reach JPY 195.2 billion ($1.31 billion) sales in fiscal year 2022, a big increase from the previous JPY 128.4 billion forecast.

Daiichi Sankyo is a commercial-stage biopharmaceutical company that is in strong financial health. As of fiscal 2022, it had a debt/EBITDA ratio of 0.89 times and over JPY 800 billion in cash and ...

Enhertu logged sales of $3.75 billion in Daiichi’s 2024 fiscal year, which concluded at the end of March. The company is projecting sales of the treatment to reach 662 billion Japanese yen in ...

The AstraZeneca and Daiichi Sankyo targeted cancer drug Enhertu is now the first therapy in its class approved for treating solid tumors regardless of either the cancer type or where the disease ...

Enhertu is currently approved as a second-line treatment for HER2-positive metastatic breast cancer. The new results for the AstraZeneca and Daiichi Sankyo drug in the first-line setting are ...

AZ's confidence in the potential of Enhertu is evidence from the terms of its late 2019 licensing deal with Daiichi Sankyo, which included a hefty $1.35 billion upfronting a deal that could be ...

Enhertu brought in $2.57 billion in combined sales for both AstraZeneca and Daiichi Sankyo in 2023, doubling from the $1.25 billion in 2022. But that growth appears to have slowed a bit in 2024, with ...

Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) ENHERTU (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with unresectable or ...

MADRID—Daiichi Sankyo and ADC partner AstraZeneca finally have some clarity on the deaths that occurred in a pair of phase 3 studies for their Enhertu follow up Dato-DXd.